Drugs.com - Clinical Trials

Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function

MINNEAPOLIS, MN -- January 22, 2025 -- Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in COVID-19 patients recently...

Feb 9, 2025 - 21:44
 0
Humanetics Corporation Announces Positive Phase 2 Clinical Trial Results in COVID-19 Study Aimed at Improving Pulmonary Function
MINNEAPOLIS, MN -- January 22, 2025 -- Humanetics Corporation (Humanetics) announced today the results of its Phase 2 clinical trial of BIO 300 Oral Suspension (BIO 300) for the mitigation of impaired pulmonary function in COVID-19 patients recently...
Read More

Tags:

Previous Article

Tris Pharma Announces Positive Results from ALLEVIATE-1 Phase 3 Clinical Trial o...

Next Article

Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Pha...

Related Posts

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Announces Positive Topline Results From Phase...

Feb 9, 2025  0

Boehringer’s Nerandomilast Meets Primary Endpoint in Phase III Study FIBRONEER™-ILD, in Progressive Pulmonary Fibrosis

Boehringer’s Nerandomilast Meets Primary Endpoint in Ph...

Feb 10, 2025  0

Zydus Announces USFDA Orphan Drug Designation to Usnoflast for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Zydus Announces USFDA Orphan Drug Designation to Usnofl...

Feb 9, 2025  0